Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories
Patients with B-cell chronic lymphocytic leukemia (CLL) with 17p deletion respond poorly to chemotherapy. This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL in the various cytogenetic subgroups. Data were collected from 105 consecutive,...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2010-12, Vol.21 (12), p.2410-2419 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2419 |
|---|---|
| container_issue | 12 |
| container_start_page | 2410 |
| container_title | Annals of oncology |
| container_volume | 21 |
| creator | Fiegl, M. Erdel, M. Tinhofer, I. Brychtova, Y. Panovska, A. Doubek, M. Eigenberger, K. Fonatsch, C. Hopfinger, G. Mühlberger, H. Zabernigg, A. Falkner, F. Gastl, G. Mayer, J. Greil, R. |
| description | Patients with B-cell chronic lymphocytic leukemia (CLL) with 17p deletion respond poorly to chemotherapy. This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL in the various cytogenetic subgroups.
Data were collected from 105 consecutive, pretreated, cytogenetically defined patients who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) were assessed.
The hierarchic incidence of cytogenetic abnormalities was: 13q deletion (as sole abnormality), 18%; trisomy 12, 13%; 11q deletion, 19%; 17p deletion, 33%; and none of these, 16%. Overall response rate (ORR) was 43% in the total cohort and 49% in the subgroup of 17p-deleted patients (n = 35). From the start of alemtuzumab monotherapy, median PFS in the total cohort and in the subgroup of 17p-deleted patients was 7.0 and 7.1 months, respectively. Median OS in the total cohort and in 17p-deleted patients was 32.8 and 19.1 months, respectively. The poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n = 20) showed encouraging ORR, PFS, and OS (35%, 7.0 and 19.2 months, respectively).
Alemtuzumab was effective in treating patients with CLL across the cytogenetic categories evaluated, but there were differences. In patients with CLL with 17p deletion quite favorable ORR, PFS, and OS were achieved. |
| doi_str_mv | 10.1093/annonc/mdq236 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_816387016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419392488</els_id><sourcerecordid>816387016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c546t-3a8dbf0d96fc73e06aa00817600bf389f172db43653be6ff2c0dd997e5e723383</originalsourceid><addsrcrecordid>eNp9kU2P0zAQhi0EYkvhyBX5guAS1okTO-HGVkCRFhDiQ4iL5djj1jSJs7ZTCD-G34qrlt0TXGxL8-idGT8IPczJs5w09FwOgxvUea-vCspuoUVesSarSZnfRgvSFDTjFS3P0L0QvhNCWFM0d9FZQUrGeFkt0O9VZwerZIfdFJXrATuDRw_Rg4yg8UWmoOuw2nqXMNzN_bh1ao6HN0w76K3ExnWd-2GHDZYd9HH6NfWyxXELXo7zcyzxIc6FEVS0e8AhTnrGbsB76a2bAk5xbgMDHEK9DTusUuuN8xbCfXTHyC7Ag9O9RJ9fvfy0WmeX71-_Wb24zFRVsphRWevWEN0wozgFwqQkpM45I6Q1tG5MzgvdlpRVtAVmTKGI1k3DoQJeUFrTJXpyzB29u5ogRNHbcNhcDpBGFHXOaM1JOpfo6X_JvGRlRVjNaEKzI6rS9sGDEaO3vfSzyIk4yBNHeeIoL_GPTtFT24O-pv_aSsDjEyBDUma8HJQNN1zaLy9KdtPYhgg_r-vS7wTjlFdi_fWb-HixLup3bz-IL4nnRx7SF-8teBGUhUGBtj5JE9rZf4z8B3hOy-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1464506863</pqid></control><display><type>article</type><title>Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Fiegl, M. ; Erdel, M. ; Tinhofer, I. ; Brychtova, Y. ; Panovska, A. ; Doubek, M. ; Eigenberger, K. ; Fonatsch, C. ; Hopfinger, G. ; Mühlberger, H. ; Zabernigg, A. ; Falkner, F. ; Gastl, G. ; Mayer, J. ; Greil, R.</creator><creatorcontrib>Fiegl, M. ; Erdel, M. ; Tinhofer, I. ; Brychtova, Y. ; Panovska, A. ; Doubek, M. ; Eigenberger, K. ; Fonatsch, C. ; Hopfinger, G. ; Mühlberger, H. ; Zabernigg, A. ; Falkner, F. ; Gastl, G. ; Mayer, J. ; Greil, R. ; for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL ; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL</creatorcontrib><description>Patients with B-cell chronic lymphocytic leukemia (CLL) with 17p deletion respond poorly to chemotherapy. This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL in the various cytogenetic subgroups.
Data were collected from 105 consecutive, pretreated, cytogenetically defined patients who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) were assessed.
The hierarchic incidence of cytogenetic abnormalities was: 13q deletion (as sole abnormality), 18%; trisomy 12, 13%; 11q deletion, 19%; 17p deletion, 33%; and none of these, 16%. Overall response rate (ORR) was 43% in the total cohort and 49% in the subgroup of 17p-deleted patients (n = 35). From the start of alemtuzumab monotherapy, median PFS in the total cohort and in the subgroup of 17p-deleted patients was 7.0 and 7.1 months, respectively. Median OS in the total cohort and in 17p-deleted patients was 32.8 and 19.1 months, respectively. The poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n = 20) showed encouraging ORR, PFS, and OS (35%, 7.0 and 19.2 months, respectively).
Alemtuzumab was effective in treating patients with CLL across the cytogenetic categories evaluated, but there were differences. In patients with CLL with 17p deletion quite favorable ORR, PFS, and OS were achieved.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdq236</identifier><identifier>PMID: 20466745</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Alemtuzumab ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antibodies, Neoplasm - adverse effects ; Antibodies, Neoplasm - therapeutic use ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Chemotherapy, Adjuvant ; Chromosome Aberrations - statistics & numerical data ; chronic lymphocytic leukemia ; cytogenetic abnormalities ; Disease Progression ; Drug-Related Side Effects and Adverse Reactions - genetics ; Female ; FISH ; Genetic Predisposition to Disease ; Hematologic and hematopoietic diseases ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - genetics ; Leukemia, Lymphocytic, Chronic, B-Cell - mortality ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Survival Analysis ; Treatment Outcome</subject><ispartof>Annals of oncology, 2010-12, Vol.21 (12), p.2410-2419</ispartof><rights>2010 European Society for Medical Oncology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c546t-3a8dbf0d96fc73e06aa00817600bf389f172db43653be6ff2c0dd997e5e723383</citedby><cites>FETCH-LOGICAL-c546t-3a8dbf0d96fc73e06aa00817600bf389f172db43653be6ff2c0dd997e5e723383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23651246$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20466745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fiegl, M.</creatorcontrib><creatorcontrib>Erdel, M.</creatorcontrib><creatorcontrib>Tinhofer, I.</creatorcontrib><creatorcontrib>Brychtova, Y.</creatorcontrib><creatorcontrib>Panovska, A.</creatorcontrib><creatorcontrib>Doubek, M.</creatorcontrib><creatorcontrib>Eigenberger, K.</creatorcontrib><creatorcontrib>Fonatsch, C.</creatorcontrib><creatorcontrib>Hopfinger, G.</creatorcontrib><creatorcontrib>Mühlberger, H.</creatorcontrib><creatorcontrib>Zabernigg, A.</creatorcontrib><creatorcontrib>Falkner, F.</creatorcontrib><creatorcontrib>Gastl, G.</creatorcontrib><creatorcontrib>Mayer, J.</creatorcontrib><creatorcontrib>Greil, R.</creatorcontrib><creatorcontrib>for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL</creatorcontrib><creatorcontrib>Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL</creatorcontrib><title>Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Patients with B-cell chronic lymphocytic leukemia (CLL) with 17p deletion respond poorly to chemotherapy. This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL in the various cytogenetic subgroups.
Data were collected from 105 consecutive, pretreated, cytogenetically defined patients who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) were assessed.
The hierarchic incidence of cytogenetic abnormalities was: 13q deletion (as sole abnormality), 18%; trisomy 12, 13%; 11q deletion, 19%; 17p deletion, 33%; and none of these, 16%. Overall response rate (ORR) was 43% in the total cohort and 49% in the subgroup of 17p-deleted patients (n = 35). From the start of alemtuzumab monotherapy, median PFS in the total cohort and in the subgroup of 17p-deleted patients was 7.0 and 7.1 months, respectively. Median OS in the total cohort and in 17p-deleted patients was 32.8 and 19.1 months, respectively. The poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n = 20) showed encouraging ORR, PFS, and OS (35%, 7.0 and 19.2 months, respectively).
Alemtuzumab was effective in treating patients with CLL across the cytogenetic categories evaluated, but there were differences. In patients with CLL with 17p deletion quite favorable ORR, PFS, and OS were achieved.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alemtuzumab</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antibodies, Neoplasm - adverse effects</subject><subject>Antibodies, Neoplasm - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Chromosome Aberrations - statistics & numerical data</subject><subject>chronic lymphocytic leukemia</subject><subject>cytogenetic abnormalities</subject><subject>Disease Progression</subject><subject>Drug-Related Side Effects and Adverse Reactions - genetics</subject><subject>Female</subject><subject>FISH</subject><subject>Genetic Predisposition to Disease</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2P0zAQhi0EYkvhyBX5guAS1okTO-HGVkCRFhDiQ4iL5djj1jSJs7ZTCD-G34qrlt0TXGxL8-idGT8IPczJs5w09FwOgxvUea-vCspuoUVesSarSZnfRgvSFDTjFS3P0L0QvhNCWFM0d9FZQUrGeFkt0O9VZwerZIfdFJXrATuDRw_Rg4yg8UWmoOuw2nqXMNzN_bh1ao6HN0w76K3ExnWd-2GHDZYd9HH6NfWyxXELXo7zcyzxIc6FEVS0e8AhTnrGbsB76a2bAk5xbgMDHEK9DTusUuuN8xbCfXTHyC7Ag9O9RJ9fvfy0WmeX71-_Wb24zFRVsphRWevWEN0wozgFwqQkpM45I6Q1tG5MzgvdlpRVtAVmTKGI1k3DoQJeUFrTJXpyzB29u5ogRNHbcNhcDpBGFHXOaM1JOpfo6X_JvGRlRVjNaEKzI6rS9sGDEaO3vfSzyIk4yBNHeeIoL_GPTtFT24O-pv_aSsDjEyBDUma8HJQNN1zaLy9KdtPYhgg_r-vS7wTjlFdi_fWb-HixLup3bz-IL4nnRx7SF-8teBGUhUGBtj5JE9rZf4z8B3hOy-U</recordid><startdate>20101201</startdate><enddate>20101201</enddate><creator>Fiegl, M.</creator><creator>Erdel, M.</creator><creator>Tinhofer, I.</creator><creator>Brychtova, Y.</creator><creator>Panovska, A.</creator><creator>Doubek, M.</creator><creator>Eigenberger, K.</creator><creator>Fonatsch, C.</creator><creator>Hopfinger, G.</creator><creator>Mühlberger, H.</creator><creator>Zabernigg, A.</creator><creator>Falkner, F.</creator><creator>Gastl, G.</creator><creator>Mayer, J.</creator><creator>Greil, R.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20101201</creationdate><title>Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories</title><author>Fiegl, M. ; Erdel, M. ; Tinhofer, I. ; Brychtova, Y. ; Panovska, A. ; Doubek, M. ; Eigenberger, K. ; Fonatsch, C. ; Hopfinger, G. ; Mühlberger, H. ; Zabernigg, A. ; Falkner, F. ; Gastl, G. ; Mayer, J. ; Greil, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c546t-3a8dbf0d96fc73e06aa00817600bf389f172db43653be6ff2c0dd997e5e723383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alemtuzumab</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antibodies, Neoplasm - adverse effects</topic><topic>Antibodies, Neoplasm - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Chromosome Aberrations - statistics & numerical data</topic><topic>chronic lymphocytic leukemia</topic><topic>cytogenetic abnormalities</topic><topic>Disease Progression</topic><topic>Drug-Related Side Effects and Adverse Reactions - genetics</topic><topic>Female</topic><topic>FISH</topic><topic>Genetic Predisposition to Disease</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - genetics</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fiegl, M.</creatorcontrib><creatorcontrib>Erdel, M.</creatorcontrib><creatorcontrib>Tinhofer, I.</creatorcontrib><creatorcontrib>Brychtova, Y.</creatorcontrib><creatorcontrib>Panovska, A.</creatorcontrib><creatorcontrib>Doubek, M.</creatorcontrib><creatorcontrib>Eigenberger, K.</creatorcontrib><creatorcontrib>Fonatsch, C.</creatorcontrib><creatorcontrib>Hopfinger, G.</creatorcontrib><creatorcontrib>Mühlberger, H.</creatorcontrib><creatorcontrib>Zabernigg, A.</creatorcontrib><creatorcontrib>Falkner, F.</creatorcontrib><creatorcontrib>Gastl, G.</creatorcontrib><creatorcontrib>Mayer, J.</creatorcontrib><creatorcontrib>Greil, R.</creatorcontrib><creatorcontrib>for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL</creatorcontrib><creatorcontrib>Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fiegl, M.</au><au>Erdel, M.</au><au>Tinhofer, I.</au><au>Brychtova, Y.</au><au>Panovska, A.</au><au>Doubek, M.</au><au>Eigenberger, K.</au><au>Fonatsch, C.</au><au>Hopfinger, G.</au><au>Mühlberger, H.</au><au>Zabernigg, A.</au><au>Falkner, F.</au><au>Gastl, G.</au><au>Mayer, J.</au><au>Greil, R.</au><aucorp>for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL</aucorp><aucorp>Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2010-12-01</date><risdate>2010</risdate><volume>21</volume><issue>12</issue><spage>2410</spage><epage>2419</epage><pages>2410-2419</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Patients with B-cell chronic lymphocytic leukemia (CLL) with 17p deletion respond poorly to chemotherapy. This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL in the various cytogenetic subgroups.
Data were collected from 105 consecutive, pretreated, cytogenetically defined patients who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) were assessed.
The hierarchic incidence of cytogenetic abnormalities was: 13q deletion (as sole abnormality), 18%; trisomy 12, 13%; 11q deletion, 19%; 17p deletion, 33%; and none of these, 16%. Overall response rate (ORR) was 43% in the total cohort and 49% in the subgroup of 17p-deleted patients (n = 35). From the start of alemtuzumab monotherapy, median PFS in the total cohort and in the subgroup of 17p-deleted patients was 7.0 and 7.1 months, respectively. Median OS in the total cohort and in 17p-deleted patients was 32.8 and 19.1 months, respectively. The poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n = 20) showed encouraging ORR, PFS, and OS (35%, 7.0 and 19.2 months, respectively).
Alemtuzumab was effective in treating patients with CLL across the cytogenetic categories evaluated, but there were differences. In patients with CLL with 17p deletion quite favorable ORR, PFS, and OS were achieved.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>20466745</pmid><doi>10.1093/annonc/mdq236</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2010-12, Vol.21 (12), p.2410-2419 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_816387016 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Alemtuzumab Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antibodies, Neoplasm - adverse effects Antibodies, Neoplasm - therapeutic use Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy Chemotherapy, Adjuvant Chromosome Aberrations - statistics & numerical data chronic lymphocytic leukemia cytogenetic abnormalities Disease Progression Drug-Related Side Effects and Adverse Reactions - genetics Female FISH Genetic Predisposition to Disease Hematologic and hematopoietic diseases Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Pharmacology. Drug treatments Retrospective Studies Risk Assessment Risk Factors Survival Analysis Treatment Outcome |
| title | Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A16%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcome%20of%20pretreated%20B-cell%20chronic%20lymphocytic%20leukemia%20following%20alemtuzumab%20therapy:%20a%20retrospective%20study%20on%20various%20cytogenetic%20risk%20categories&rft.jtitle=Annals%20of%20oncology&rft.au=Fiegl,%20M.&rft.aucorp=for%20The%20Austrian%20Collaborative%20Study%20Group%20on%20Alemtuzumab%20in%20Chronic%20Lymphocytic%20Leukemia,%20in%20cooperation%20with%20The%20Czech%20Leukemia%20Study%20Group%20for%20Life,%20CELL&rft.date=2010-12-01&rft.volume=21&rft.issue=12&rft.spage=2410&rft.epage=2419&rft.pages=2410-2419&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdq236&rft_dat=%3Cproquest_cross%3E816387016%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1464506863&rft_id=info:pmid/20466745&rft_els_id=S0923753419392488&rfr_iscdi=true |